Physician profile
Terra Leight
NPI 1447781315
$2,072.55
in general payments reported to CMS, 2019-2025
21 companies · $391 in 2025
The $391 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $40.96 · 2021: $561 · 2022: $625 · 2023: $161 · 2024: $182 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $734.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $318.27 | 2022-2025 | Rocklatan, Tryptyr, Simbrinza |
| Sight Sciences, INC. | $312.43 | 2022 | |
| Allergan, INC. | $227.92 | 2020-2021 | |
| Abbvie INC. | $161.47 | 2022-2025 | |
| Ivantis, INC | $135.38 | 2021 | |
| Bausch & Lomb Americas INC. | $133.02 | 2024-2025 | Xiidra, Miebo, Scoutpro Osmolarity System |
| Novartis Pharmaceuticals Corporation | $117.54 | 2020-2022 | |
| Aerie Pharmaceuticals, INC. | $112.03 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $106.89 | 2021 | |
| Oyster Point Pharma, INC. | $102.97 | 2022-2025 | Tyrvaya, Ryzumvi |
| Harrow Eye, LLC | $99.63 | 2025 | Vevye |
| Regeneron Healthcare Solutions, INC. | $32.54 | 2019 | |
| Dompe US, INC. | $30.94 | 2021-2025 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $28.73 | 2019 | |
| Biotissue Holdings INC. | $25.00 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $24.43 | 2022 | |
| Kedrion Biopharma, INC. | $23.29 | 2025 | Rhogam Ultra-Filtered Plus, Gammaked, Albuked |
| Eyevance Pharmaceuticals LLC | $22.81 | 2023 | Flarex |
| Thea Pharma INC. | $22.54 | 2025 | Iyuzeh |
| Ocular Therapeutix, INC. | $19.06 | 2023 | Dextenza |
| Coopervision INC. | $15.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terra Leight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.